Concurrently, loss of the apical-basolateral CP raises tumor resistance to trastuzumab by enhancing MUC1-C (carboxy-terminal transmembrane subunit of mucin 1) interaction with mislocalized HER2 [78]. This evidence concerns the gene CP and neoplasm.